ALFA Finder| Revenue growth | FY27 guided at ₹2,200-2,400cr. |
|---|---|
| Margins | Targeting 12-14% EBITDA for FY27 vs 5% in Q4. |
| Order book | Large order book across businesses; 300 MT Ethyl Vanillin for Q1. |
| Demand visibility | Strong order book for Ethyl Vanillin; 50% of campaign covered. |
| Management confidence | High on Blends and Vanillin scaling despite macro headwinds. |
Growth
FY26 revenue reached ₹1,723cr; Blends grew 17% (18% including Europe). Q4 EBITDA at ₹21cr (5% margin).
Outlook
FY27 revenue guidance ₹2,200-2,400cr with 12-14% EBITDA margins. Vanillin volume target 2,200-2,400 MT for U.S.
Risks
Geopolitical conflicts causing 20% shipment delays, high freight costs, and raw material (Phenol/Caustic) price spikes.
Earnings Call filed with BSE, NSE: CAMLINFINE. Summary written with AI assistance from the document.
Camlin Fine Sciences Ltd: key numbers
- Share price
- ₹76.87
- Market cap
- ₹1,477 Cr
- Revenue (annual)
- ₹1,723 Cr
- Net profit (annual)
- ₹27.63 Cr
- P/E (TTM)
- -194.6×Sector 35.1×
- Promoter holding
- 48.03%+0.00% QoQ
- FII holding
- 0.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Camlin Fine Sciences Ltd
All →Camlin Fine Sciences Share Pledge
Camlin Fine Sciences promoter-director Ashish Dandekar pledged 3,70,000 shares valued at ₹2.93 Crore. Reported holding stays at 10.30% before and after the pledge.
- Value
- ₹2.93 Cr
Camlin Fine Sciences Earnings Call Transcript: Key Takeaways
EBITDA margin collapsed to about 0.5% from 3.4% as liquidity stress hit gross margin. A ₹250 Cr rights issue is pitched as the fix, and Q3 is described as a fight to stay afloat.
Camlin Fine Sciences Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs4,915mn (+9.2% YoY), but EBITDA margin fell to 0.45% and PAT loss was Rs281mn. Rights issue up to Rs2,500mn approved.
Camlin Fine Sciences Q2 FY27 Results: Net Loss of ₹29.7 Cr, Loss Widens
Camlin Fine Sciences Ltd reported revenue from operations of ₹491.5 Cr (+9.1% YoY) and a net loss of ₹29.7 Cr for Q2 FY27.
- Key figure
- Net loss ₹29.7 Cr
Camlin Fine Sciences Legal & Regulatory
SEBI issued an administrative warning to Camlin Fine Sciences over misclassified promoter-group shareholders in filings. No monetary penalty; compliance must improve to avoid enforcement.
Camlin Fine Sciences Board Meeting Date
Camlin Fine Sciences' board meets on 03 Nov 2026 to consider results and a proposed rights issue. Trading window closes until 05 Nov 2026.